Literature DB >> 1848478

Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.

J Y Chang1, F S Han, S Y Liu, Z Q Wang, K H Lee, Y C Cheng.   

Abstract

Six 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin were examined for inhibitory activity against human DNA topoisomerase II and tubulin polymerization, their ability to generate protein-linked DNA breaks in cells, and their cytotoxicity toward the KB cell line and its VP-16- and vincristine-resistant variants. Five of these derivatives were 5- to 10-fold more potent than VP-16 as inhibitors of DNA topoisomerase II in vitro, and all of these derivatives could generate the same amount of or more protein-linked DNA breaks in cells than VP-16 at 1-20 microMs. Tubulin polymerization was inhibited by these compounds to different degrees in the order: podophyllotoxin greater than W73 greater than W87 greater than NPF greater than NPC greater than W68 greater than W38 greater than VP-16. These analogues were cytotoxic not only to KB cells but also to their VP-16-resistant and vincristine-resistant variants which showed decreased cellular uptake of VP-16 and a decrease in DNA topoisomerase II content or overexpression of MDR1 phenotype. These characteristics may cause these derivatives to have different spectrums of antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Plant-derived natural product research aimed at new drug discovery.

Authors:  Hideji Itokawa; Susan L Morris-Natschke; Toshiyuki Akiyama; Kuo-Hsiung Lee
Journal:  J Nat Med       Date:  2008-04-22       Impact factor: 2.343

2.  A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells.

Authors:  T S Huang; C C Lee; Y Chao; C H Shu; L T Chen; L L Chen; M H Chen; C C Yuan; J Whang-Peng
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 3.  Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.

Authors:  Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

4.  A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.

Authors:  C C Lee; T S Huang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 5.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y C Shen; H X Chen; J Y Chang; X Guo; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

Review 7.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

8.  Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.

Authors:  Malgorzata N Drwal; Jessica Marinello; Stefano G Manzo; Laurence P G Wakelin; Giovanni Capranico; Renate Griffith
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.